You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.
Halozyme Therapeutics director to step down
Gauging Supply Chain Risk In Volatile Times
Cannabis: Hashing Out a Budding Industry
IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help
The Market Intelligence Platform
Randal Kirk informed Halozyme Therapeutics Inc. of his unavailability to serve as a director due to his growing commitments outside of the company.
Due to this development, Kirk will not be nominated for re-election to the board at the upcoming stockholders' annual meeting.
San Diego, Calif.-based Halozyme Therapeutics is a biotechnology company which researches, develops, and commercializes human enzymes and other drug candidates in the U.S., Switzerland, and internationally.